Drugs / Pentaglobin
Pentaglobin
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03494959 | Dec 2019 → May 2024 overdue | infectious disease with sepsis | Italian Group for Bone Marrow Transplantation | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04351724 | Apr 2020 → Dec 2021 | COVID-19 | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04182737 | May 2020 → Feb 2022 | immunodeficiency disease, infectious disease with sepsis | Massimo Girardis | Unknown | No outcome recorded |
| Phase 3 | NCT04041765 | Sep 2019 → Jun 2020 | neonatal sepsis | Faculty of Medicine, University of Indonesia | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01867645 Comparator | Dec 2004 → Apr 2009 | polyneuropathy | Medical University of Vienna | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03334006 Comparator | Nov 2017 → Sep 2027 expected | infectious disease with sepsis, peritonitis | RWTH Aachen University | Recruiting | No outcome recorded |
| Phase 2 | NCT02655133 Comparator | Jan 2016 → Jan 2018 | infectious disease with sepsis | Marche Polytechnic University | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT03403530 Comparator | Jan → Jun 2018 | neonatal sepsis | Sir Takhtasinhji General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01006499 Comparator | Aug 2009 → Oct 2010 | neonatal sepsis | Zekai Tahir Burak Women's Health Research and Education Hospital | Unknown | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pentaglobin | “IgM-enriched IVIG (Pentaglobin, Biotest Pharma GmbH, Dreieich, Germany) at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion” NCT01867645 ↗ |
| Known as | IgGAM | “In addition, these biomarkers could help to guide a targeted, i.e. "personalized", adjuvant therapy with Pentaglobin® (IgGAM) in the indication of peritonitis.” NCT03334006 ↗ |
| Known as | IgM preparation | “The treatment given to patients of both groups during this independent study will be the IgM-enriched immunoglobulin preparation (IgM preparation) (Pentaglobin®, Biotest,...” NCT04182737 ↗ |
| Known as | IgM rich Immunoglobin | “Drug: IgM rich Immunoglobin” NCT03403530 ↗ |
| Known as | IgM-enriched Intravenous Immunoglobulins | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01867645 ↗ |
| Known as | IgM-enriched IVIG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04041765 ↗ |
| Known as | IgM-enriched polyclonal immunoglobulins | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04182737 ↗ |
| Modality | Protein / enzyme biologic | “IgM enriched IVIG” NCT01006499 ↗ |
| Route | Intravenous | “Standard treatment plus 250 mg/Kg of Pentaglobin intravenously (given over 4 hours) daily for three days” NCT01006499 ↗ |